I-Corps: Multiplex diagnostic assay using interdigitated nano-sensing technology implemented point-of-care device

I-Corps项目更广泛的影响/商业潜力是开发使用交叉指状纳米传感技术进行护理点诊断的多重诊断分析和设备。拟议的初步应用是卵巢癌的检测和监测。卵巢癌的早期诊断很困难，因为良性疾病通常会混淆其症状。目前，美国约有25万名女性患有卵巢癌，卵巢癌复发的可能性超过70%。该技术可提供卵巢癌的早期检测和监测功能，以提高生存率，挽救数千名妇女的生命。此外，拟议的诊断平台可能会扩大到商业诊断实验室检测许多其他疾病，如其他癌症、疟疾和新冠肺炎。据设想，拟议的技术可以在医院和医疗中心以及医生办公室、药房和药店使用，这可能会使它更容易获得，并可能挽救更多的生命，改善患者的生活质量和医疗环境。这个i-Corps项目基于开发一种使用交叉式纳米传感技术的多重诊断分析和设备，用于医疗保健点诊断。该技术的目的是在设备的微通道中自发分离生物分子，并高精度地检测多个生物标志物。这项拟议的技术最初将用于卵巢癌的检测，并通过在极低的检测下限(微微水平)量化卵巢癌的各种生物标记物的浓度来工作。它是一个独立的设备，由两个主要组件组成：一个是能够在毛细血管血流中自发分离血浆的微流控通道，另一个是集成了微通道的生物传感平台，该微通道包含多个纳米生物传感器，用于检测分离血浆中皮级浓度的各种抗原。建议的技术可用于准确测试目标生物标记物的浓度，帮助癌症的早期诊断，以及在监测过程中评估治疗效果。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is the development of the multiplex diagnostic assay and device using interdigitated nano-sensing technology for point-of-care diagnostics. The proposed initial application is the detection and monitoring of ovarian cancer. The early diagnosis of ovarian cancer is difficult because the benign condition usually obfuscates its symptoms. Currently, there are approximately 250,000 women living with ovarian cancer in the U.S., and ovarian cancer has more than a 70% chance to recur. The proposed technology may provide early detection of the ovarian cancer and monitoring functions to improve the survival rate and save thousands of women lives. In addition, the proposed diagnostic platform may be expanded to detect many other diseases, such as other cancers, malaria, and Covid-19, at commercial diagnostic laboratories. It is envisioned that the proposed technology may be used in hospitals and medical centers as well as physician's offices, pharmacies, and drug stores, which may make it more accessible and may save more lives and improve the quality of patients’ lives and health care environment.This I-Corps project is based on the development of a multiplex diagnostic assay and device using interdigitated nano-sensing technology for point-of-care diagnostics. The proposed technology is designed to separate biomolecules spontaneously in the microchannel of the device and detect multiplex biomarkers with high accuracy. The proposed technology initially will be used to test for ovarian cancer, and works by quantifying the concentrations of various biomarkers for ovarian cancer at an extremely low limit of detection (pico-level). It is a standalone device that consists of two main components: a microfluidic channel that is capable to separate the blood plasma spontaneously in the capillary blood flow, and a biosensing platform integrated with microchannels that contain multiple nano-biosensors used to detect various antigens at pico-level concentrations in the separated plasma. The proposed technology may be used to accurately test the concentration of targeted biomarkers and assist in the early diagnosis of cancer as well evaluate the efficacy of the treatment during the monitoring process.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.